The CMS rule narrows the mandatory international price benchmarking model's scope, reducing projected savings versus earlier drafts.

The order adds trade pressure on drugmakers already facing most-favored-nation pricing demands.

Boehringer reiterated support for the candidate despite the second disappointing late-stage readout for the partnership.

Deeper phase 3 results for Lilly's oral GLP-1 come as new obesity and diabetes studies dominate the European EASD meeting.

The move removes a high-profile oral obesity candidate from Pfizer's pipeline as the GLP-1 field consolidates.

The licensing deal adds a China-origin weekly oral candidate to Novo's obesity pipeline amid intensifying competition.

The label expansion moves the BTK inhibitor into first-line use for a subset of chronic lymphocytic leukemia patients.

The accelerated nod adds a new option in multiple myeloma, a crowded but high-value hematology market.

Lilly's GLP-1 franchise continues to drive steep growth, with attention on how it reinvests the proceeds, including in China.

A one-year data check could enable faster approval for the RNA editing therapy in alpha-1 antitrypsin deficiency.

The device is the first expandable valve cleared for pediatric patients, a small but underserved cardiac segment.

The filing follows phase 3 REZILIENT3 results for the combo in first-line EGFR exon 20 insertion lung cancer.

The pivot follows a prior obesity partnership with Novo Nordisk, redirecting the company toward neurology.

The trial result reinforces Novo's GLP-1 portfolio as it defends share against Lilly and new entrants.

The mid-stage data extends the obesity drug class into a women's health indication beyond weight loss.

The split affects cell therapy manufacturing capacity for BMS's CAR-T franchise.

The executive action signals a lighter regulatory path for psychedelic-based treatments.

The partner's public support aims to steady confidence in the program after a weak phase 3 result.